Navigation Links
Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

http://www.reportlinker.com/p0968567/Market-and-Product-Forecasts-Top-20-Oncology-Therapy-Brands-2011-21---Avastin-fails-to-top-any-individual-market-in-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy  

The high level of commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. Treatment of cancer has shifted toward a more focused attack on the disease with targeted therapies. However, austerity packages imposed could see slower commercial growth and larger generic erosion of key brands.Analysis of the top 20 oncology therapy brands in the seven major marketsIn depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major marketsSales forecasts for the top 20 cancer therapy brands from 2011 to 2021Brand dynamics and assessment of the top 5 cancer brands in the seven major marketsThe total sales of the top 20 cancer therapy brands in the seven major markets was $37.2bn in 2011, with targeted therapies representing 74% of those sales. However, the oncology market is fragmenting as developers focus on niche subsets of patients with specific genetic mutations, making it harder for drugs to reach blockbuster status.Targeted therapies dominated the market, and will increase their share of the top 20 as patent expiries continue to impact sales of other drug classes. Generic erosion of multiple key brands in the cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales from 17% in 2011 to 10% in 2021.Avastin did not achieve the top position in any of the individual markets, the US, Japan, or 5EU, due to a combination of US indication removal, cost-conservative EU markets, strong antihormonal sales in Japan, and tough Swiss Franc exchange rates.Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2011 and 2021.Acquire an account of top-selling cancer brand dynamics and the events that drive and limit their market growth.The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top 20 forecasts for the US, Japan and 5EU.

 

OVERVIEW•Catalyst

•Summary

 

EXECUTIVE SUMMARY•Strategic scoping and focus

•Datamonitor key findings

•Related reports

 

MARKET DEFINITION •Market definition for cancer therapies - Antihormonal therapies by ATC class

- Cytotoxic therapies by ATC class

- Targeted therapies by ATC class

 

•Forecast methodology and assumptions - Methodology flow

- Patent expiries

 

•Additional forecast methodology

 

MARKET OVERVIEW AND CONTEXT•Cancer therapy brands included in this report

•Seven major markets top 20 oncology therapy brands - Targeted therapies will continue to control the seven major markets top 20

 

•US top 20 oncology therapy brands - Cytotoxic brands lose out following patent expiries as targeted therapies fragment the market

 

•Japan top 20 oncology therapy brands - Patent expiries are likely to become more significant over the forecast period

 

•Five major EU markets top 20 oncology therapy brands - Economic constraints limit sales growth of targeted therapies

 

 

PRODUCT FORECASTS•Brand dynamics - Avastin maintains overall leading position despite not topping any of the markets in 2011

 

•Avastin (bevacizumab; Roche/Chugai) - Forecast assumptions

- Avastin forecast 2011–21

 

•Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) - Forecast assumptions

- Rituxan forecast 2011–21

 

•Herceptin (trastuzumab; Roche/Chugai) - Forecast assumptions

- Herceptin forecast 2011–21

 

•Gleevec (imatinib; Novartis) - Forecast assumptions

- Gleevec forecast 2011–21

 

•Revlimid (lenalidomide; Celgene) - Forecast assumptions

- Revlimid forecast 2011–21

 

•Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) - Forecast assumptions

- Erbitux forecast 2011–21

 

•Lupron (leuprolide; Takeda/Abbott) - Forecast assumptions

- Lupron forecast 2011–21

 

 

BIBLIOGRAPHY•Journal papers

•Websites

•Datamonitor reports

 

APPENDIX •Forecast methodology - Volume and value forecast methodology

- Price assumptions

 

TABLES

•Table: Definition of the cancer market, 2012

•Table: Patent expiry dates for antihormonal therapies in the top 20, 2011–21

•Table: Patent expiry dates for cytotoxic therapies in the top 20, 2011–21

•Table: Patent expiry dates for targeted therapies in the top 20, 2011–21

•Table: Drugs included in the top 20 cancer therapy brands, 2011–21

•Table: Sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011

•Table: Forecast sales of the top 20 cancer therapy brands in the seven major markets ($m), 2011–21

•Table: Sales of the top 20 cancer therapy brands in the US, 2011

•Table: Forecast sales of the top 20 cancer therapy brands in the US ($m), 2011–21

•Table: Sales of the top 20 cancer therapy brands in Japan, 2011

•Table: Forecast sales of the top 20 cancer therapy brands in Japan ($m), 2011–21

•Table: Sales of the top 20 cancer therapy brands in the five major EU markets, 2011

•Table: Forecast sales of the top 20 cancer therapy brands in the five major EU markets ($m), 2011–21

•Table: Key branded cancer therapy sales in the seven major markets, 2011 and 2021

•Table: Avastin sales, by market ($m), 2011–21

•Table: Rituxan sales, by market ($m), 2011–21

•Table: Herceptin sales, by market ($m), 2011–21

•Table: Gleevec sales, by market ($m), 2011–21

•Table: Revlimid sales, by market ($m), 2011–21

•Table: Erbitux sales, by market ($m), 2011–21

•Table: Lupron sales, by market ($m), 2011–21

 

 

FIGURES

•Figure: Company-reported sales-based forecast methodology, 2012

•Figure: Unevented and evented company-reported sales-based forecasts

•Figure: Sales of the top 20 cancer therapy brands in the seven major markets, by drug class ($m), 2011 and 2021

•Figure: Sales of the top 20 cancer therapy brands in the US, by drug class ($m), 2011 and 2021

•Figure: Sales of the top 20 cancer therapy brands in Japan, by drug class ($m), 2011 and 2021

•Figure: Sales of the top 20 cancer therapy brands in the five major EU markets by drug class ($m), 2011 and 2021

•Figure: Key branded drug sales, 2011–21

•Figure: Avastin sales, by market ($m), 2011–21

•Figure: Rituxan sales, by market ($m), 2011–21

•Figure: Herceptin sales, by market ($m), 2011–21

•Figure: Gleevec sales, by market ($m), 2011–21

•Figure: Revlimid sales, by market ($m), 2011–21

•Figure: Erbitux sales, by market ($m), 2011–21

•Figure: Lupron sales, by market ($m), 2011–21

 

Companies Mentioned

GlaxoSmithKline Plc, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Sanofi

 

To order this report:

Biological_Therapy Industry: Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Transdermal Pain Management to 2016: Products, Markets, Forecasts and Opportunities
2. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
3. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
4. Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
5. Global Drug Stores and Health and Beauty Stores Market Size and Forecast to 2016
6. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
7. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
8. Global Diabetes Care Devices Market Forecast to Reach $25.3 Billion by 2018 with 5.2% CAGR
9. US Cancer Vaccine Market Analysis
10. Eaton Scientific Teams Up with Renowned Womens Sexual Health Expert Dr. Jennifer R. Berman, MD and Berman Sexual Health to Advance Tropine 3 Trials and Marketing
11. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... SINGAPORE , BEIJING , and ... a leading commercial provider of genomic services and solutions with ... a Singapore biotechnology company; and the ... today that NovogeneAIT Genomics Singapore (NovogeneAIT) – a new joint ... whole genome sequencing (WGS) centre at Biopolis, Singapore ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health ... led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and ... to serve more consumers who are managing chronic conditions or simply want ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... 2016 , ... Bill Mull Agencies, a Wichita-based firm offering ... central Kansas, is joining the Youth Horizons organization for a charity event that ... Wichita, Youth Horizons works to empower area children from unstable, troubled, or single-parent ...
Breaking Medicine News(10 mins):